Introduction and motivation
This paper addresses grid-based integration and access of distributed data from infectious disease patient databases, literature on in-vitro and in-vivo pharmaceutical data, mutation databases, clinical trials, simulations and medical expert knowledge. Artificial Intelligence and grid technology is used to abstract knowledge from the data and provide the physicians with adaptive interactive advice on treatment applied to drug resistant HIV An important aspect of our research is to use a variety ofstatistical and numerical methods to identify relationships between HIV genetic sequences and antiviral resistanc'e to investigate consistency ofresults.
The output of the problem-solving environment (PSE) consists of a prediction of the drug sensitivity of the virus, generated by comparing the viral genotype to a relational database which contains a large number of phenotype-genotype pairs. Multivariate analyses combined with rule-based fuzzy logic are applied to the integrated data to provide ranking of patientspecific drugs. In addition, cellular automata-based simulations are used to predict the drug behaviour overtime. Access to and integration of data is done through existing Internet servers and emerging gridbased frameworks like Globus. Data presentation is done by standalone PC based software, Web-access and PDA roaming WAP access. The experiments were carried out on the DAS, a Dutch Grid testbed.
Fourty two million people worldwide have been infected with HIV and 12 million have died, over the last 20 years. Figure 1 shows the pan-epidemic extent of I-UV infections. The sheer complexity of the disease, the distribution of the data, the required automatic updates to the knowledgebase and the efficient use and integration of advanced statistical and numerical techniques necessary to assist the physician motivated us to explore the novel possibilities supported by grid technology.
In this position paper we describe ongoing research in our 3 laboratories (Utrecht, St. Petersburg and Amsterdam) addressing the development of a grid based medical decision support system. The goal of the research is to investigate novel computational methods and techniques that support the development of a user friendly integrated support system for physicians. We use emerging grid-technology to combine data discovery, data mining, statistical analyses, numerical simulation and data presentation [1] .
The paper is organized as follows. Chapter 2 describes the background of HI1V research and a prototypical rule-based approach to data analyses. In chapter 3 we give an overview of the two computational techniques we study to understand the temporal variability of HIV populations through stochastical modeling and the evolution of HIV infection and the onset of AIDS through Cellular Automata modeling. Chapter 4 describes a first approach to advanced data presentation through roaming devices such as personal digital assistants (PDA's). evaluating the effect of a new fusion inhibitor drug (T20), representing 1000 patients from whom also phenotype, genotype, viral fitness, drug levels as CD4+ and SHV-RNA patterns will be collected. The third database will be from the international multicenter Great study sponsored by Virology Networks BV, within this study the value of the Retrogram decision support program is evaluated and similar parameters a described above will be collected, within this study 360 patients will be enrolled.
Background 2.1 Clinical Aspects of HIV
Another dataset will come from the Italian Musa study, in this trial data will be collected from 450 patients followed over a year. Entry point to the trial is failing a fist or second regimen, subsequently patients will be genotyped and a new regimen will be selected on the basis of Retrogram 1.4 or the Virtual Phenotype from Virco (Belgium). Throughout the duration of the project we will collect additional datasets. These datasets may serve to fuirther refine our models and first version software and may also be use to perform validation studies.
Data Analyses
The primary goal of the data analysis is to identify patterns of mutations (or naturally occurring polymorphisms) associated with resistance to antiviral drugs and to predict the degree of in-vitro or in-vivo sensitivity to Currently there are fifteen drugs licensed for treatment of individuals infected with HIV: More than ten inhibitors have been developed which inhibit the reverse transcriptase process. These inhibitors can be classified in two sub-categories that differ in the way they inhibit the RT-enzyme, nucleoside (analogue) RT-inhibitors (NRTI) and the non-nucleoside RTinhibitors (NNRTI). These compounds inhibit the protease enzyme, which acts much later on in the HIV replication cycle than reverse transcriptase.
The protease is responsible for cleaving a long poly-protein into smaller functional proteins. The overall exposure to antiretroviral drugs has been shown to be an important factor for the degree of success for a given therapy. The overall exposure can be captured by parameters as dosage and bioavailability which will codetermine the drug level within an individual patient. Given the relationships between exposure and antiviral efficacy, variability in drug levels (which may be due to differences in patient adherence to their regimens) will contribute to virological and immunological outcome. Individuals with relatively low exposure are more likely to experience virological failure than those with a high exposure. Distribution P,n of number of mutations. The practice of HIV treatment however, has shown that the variability of the number of mutations n is high, due to the complexity of the drug combinations that has been applied. The sample estimate of distribution Pn of the number of mutations in protease is shown in the Fig. 6 . It is seen, that the distributions have a clear first peak (n = 1), and a shelf (or second peak), corresponding to n = 3 . 5. Therefore we expect that there are two groups of genomes in the database, corresponding to the low and high number of mutations. The possible interpretation of the discovered bi-modal distribution is that we have two groups of patients. One group is the "new" patientswho had one or two treatments, thus their genotype contains relative small numbers of mutations. The second group is the "old" patients, which have a long treatment history, or new patients, infected through treated HIV-1 patients [15] . Distributions of the relevant mutations P;. Distribution P,n allows describe the variability of the groups of the "new" and "old" patients, only. For a more detailed study of the virus mutations driving by the certain drugs combinations, the probabilities of Here M is the total number of genomes in the dataset. Eqn. (1) describes the marginal impact of each mutation in the total population, without any information about number and occurrences of other mutations. The probabilities of the most significant relevant mutations 4k (in decreasing order of its probability) are shown in Fig. 6 Fig. 1 . It is clearly seen that the inputs of some mutations are rather different for different n, both for the protease and RT parts of the genome. E.g., for RT, for n=J, the mutations 184V and 103N have the main input. The distribution P(" is the limit distribution from the procedure shown in Fig. 5 .
From Fig. 1 (2) The dimensionality of the related matrix, obtained from Eqn. (2), may be rather high. In order to decrease the dimensionality we consider the algebraic technique of orthogonal expansion, applied to transient probability matrices [16] . D = <>IY/2 T. (3) where 0 are the eigenvectors of matrix DDT, and 5' -of matrix DTD. It allows considering the coefficients ak = Ak as the principal components (PC) [13] , and represents the probability (2) as a series:
The values 2k shows the part of the probability, explained by k-th PC. The sum of the first k-th coefficients 2k may be interpreted as a measure of convergence of the series (4). In Table 2 the values of the first 7 2k for the RT and protease parts of the HIV-1 genome are shown. These data were obtained for the total database. It can be seen that the series (4) converges rather fast in both cases: e.g. for the RT part only the first term of the series explain more 60% of conditional probability (the first five terms explain 80%). reflects the total occurrence of the mutations in a genotype (see Fig. 6 ): for the mutations with the maximal occurrences the input to conditional probabilities of its pairs is also high. The main goal of the verification is the possibility to reproduce these features of the ensemble through the dependencies formalizing the matrix D. We compared the total occurrences of all mutations in genotypes, estimated on the initial and simulated samples, see also Fig. 6 (solid line) . It is seen, that the results of the simulation and sample are rather close.
The error of the simulation increases proportionally to absolute value of the occurrences. Nevertheless, for some cases the error of the simulation is larger then the boundary of the confidence interval. This systematic error may be explained by possible variations in matrix D for groups of the "old" and "new" patients. 
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where pg is an input of the first group of mutations (and pg is an input of the second group, ml, m2 -are maximal numbers of mutations in groups and ql, q2 -are probabilities to find each one (arbitrary) mutation in the groups. The use of Bernoulli distribution logic (based on the repetition of the independent events) is more close to the description of the mutation process, then the Poisson distribution, generally applying to description of rare events.
Temporal variability of the parameters (p,q, ,q2,m ,m2 )t of the P,n approximation by Eqn. Fig. 7 , it is clear, that generally the joint probabilities D-of the mutations is increased also; moreover, the power of increasing corresponds to the total occurrences of the mutation in the ensemble. The discrimination of the groups of "old" and "new" patients in terms of bi-modal distribution (5) allow to forecast the growth of the total number of HLV-infected people in time:
Na(t) = Nten (t) + Nopd (et),
Here £ -is the slow time parameter, which shows the rapid increasing of the new patients group in comparison with the old patients. The part of "new" patients of the sample is pg (old patients -(1 -p)) from (5) . Hence, the growth curve is:
where pg (t) = po + agt -is the linear trend with the parameters from table 3, and Nold (0) is the patients initial value of "old" (treated) patients on the beginning of the forecast.
In fig. 8 the "crucial" forecast of the HIV-1 population growth are shown. It is based on the fact that altogether 42 million people worldwide have been infected with HIV at the beginning of XXI century, and 12 million have died over the last 20 years. Moreover, not taken into account is the arising of new drugs and different prophylactic and social preventive activities for restriction of HLV-1 infection. Really, this result is qualitative only; for quantitative conclusions the more sophisticated research should be done. associated graphical representation of the Retrogram Web access is given in figure 9 . figs. 1 la, b, c, and d the user enters the patient's details. 4 .2.2 J2ME Implementation.
The same user interface is applied in the J2ME implementation. There are two main differences between the J2ME implementation and the Proxy one:
1. J2ME enables the device to communicate directly to the Retrogram server without an intermediate Proxy 2. In J2ME the client's interface is contained within the device. In the Proxy method, every time the interface should be changed, the Proxy is responsible for generating a new page.
The following pseudo code illustrates the necessary steps one should take in order to fetch an HTML page generated from a script in the remote host. Specifically here is an example illustrating how the user can login to a script in the Retrogram server and extract the cookie from the header response:
* Open an HTTP connection * Open an input stream * Make an HTTP POST request * Extract the cookie from the header response * Close the connection In the J2ME implementation of Retrogram the entire client's interface takes places in the device. The connection to the server is established in the following cases:
User login: Connection with the server is necessary in order to validate the user and/or password. The user submits the username and password, and the application judges them for their correctness by scanning the HTML response from the Retrogram server. The user submits the patient's laboratory information data. The application should connect to the server in order to submit the data, take the result (HTML format) and extract the drugs ranking. Next the user looks for the references that suggest a certain drug ranking. The database with all the references exists in the Retrogram server, therefore the connection is necessary.
The application submits to a Retrogram script the cookie and the name of the drug. The drug references are given back from the server in HTML format. The application should clean up the HTML tags and show the references as plain text. Finally the user looks for classification of the patient's substitutions. This classification is part of the Retrogram 'simulation' and thus the connection to the server is still necessary. In Figure 12 we illustrate the process of taking the drugs ranking using the J2ME method. Currently we have the J2ME version in use for different users to study the usability and extendibility. More details on the implementation can be found in reference [13] .
Conclusions and Future Work
In this paper we discussed an integrative approach to bio-medicine at large and to infectious diseases in particular. We showed how in the understanding of processes 'from molecule to man' grid technology can play a crucial role. In order to cover the fast time and spatial scales required to infer information from a molecular (genomic) level up to patient medical data, we need to apply multi-scale methods where simulation, statistical analysis, data-mining is combined in an efficient way. Moreover the required integrative approach asks for distributed data collection (e.g. FHV mutation databases, patient data, literature reports etc.) and a virtual organization (physicians, hospital administration, computational resources etc.). Also the access to and use of largescale computation (both high performance as well as distributed) is essential since many of the computations involved require near real-time response and are to complex to run on a PC or PDA. Finally data presentation is crucial in order to lower the barrier of actual usage by the physicians, here the grid technology (server-client approach) can play an important role.
Although many of the aspects discussed in this paper have proven to work in concept, the complete integration of the systems and the evaluation of dayto-day use is still under development [17] . In addition each of the underlying methods (Rule based, statistical and CA based models) remain topics of further studies. We will set-up a use-base with the system described running under various European Grid testbeds. The first testbed we will use is the so-called CrossGrid testbed that supports specific features for interactive computation, an essential ingredient for a medical decision support system.
